Clinical Trial Update: Mezigdomide Plus Ixazomib and Dexamethasone for Relapsed and Refractory Multiple Myeloma [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 trial of mezigdomide plus ixazomib and dexamethasone for relapsed and refractory multiple myeloma has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• DEXAMETHASONE (Dexamethasone)
• Mezigdomide (mezigdomide)
• ixazomib (ixazomib)

Snippet

Sponsor: Kathleen Dorritie | Conditions: Relapsed and Refractory Multiple Myeloma | Phase 1, Phase 2 | Status: WITHDRAWN